The $100 million IDEAS (Imaging Dementia — Evidence for Amyloid Scanning) Study is working closely with researchers and government officials to add three additional studies to the main project, where more than 18,000 people with cognitive deterioration but whose diagnosis is unclear are receiving a brain amyloid PET scan. Those included in the IDEAS Study can take part in one or more of the three new add-on studies. They are: The Amyloid Neuroimaging and Genetics Initiative (ANGI) Study will pair the clinical information and brain imaging data from the IDEAS Study with DNA obtained from around 3,000 study participants’ saliva samples. ANGI, funded by the Alzheimer’s Association, presents a unique scientific opportunity for new discoveries relating to brain imaging, clinical information, and genetic findings that can have a major impact on dementia care. More than 20 genes associated with risk for Alzheimer’s have been identified. But how these genes relate to amyloid deposits remains unclear. It is hoped that the research made possible by ANGI will ultimately lead to the development of new therapies that will slow or prevent cognitive impairment and dementia. All participation in the study is done by phone and mail so participants don’t need to leave their homes.